Patents by Inventor Matthias Grell

Matthias Grell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8410143
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 2, 2013
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Patent number: 8158799
    Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in Claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumors.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: April 17, 2012
    Assignee: Merck Patent Gesellschaft MIT Meschraenkter Haftung
    Inventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
  • Publication number: 20110177027
    Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 21, 2011
    Inventors: Matthias GRELL, Simon GOODMAN, Curzio RUEGG
  • Publication number: 20110165150
    Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: January 18, 2006
    Publication date: July 7, 2011
    Applicant: Merck Patent GmbH
    Inventors: Simon Goodman, Matthias Grell, Timo L.M. Ten Hagen, Alexander M.M. Eggermont
  • Patent number: 7691870
    Abstract: The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg
  • Patent number: 7691886
    Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Matthias Wiesner, Lars Thore Burgdorf, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Publication number: 20090298885
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 3, 2009
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Publication number: 20090253688
    Abstract: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: February 14, 2005
    Publication date: October 8, 2009
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Frank Stieber, Matthias Wiesner, Christiane Amendt, Christian Sirrenberg, Frank Zenke, Matthias Grell
  • Patent number: 7598274
    Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: October 6, 2009
    Assignee: Merck Patent GmbH
    Inventors: Dirk Finsinger, Hans-Peter Buchstaller, Lars Burgdorf, Matthias Wiesner, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Patent number: 7589112
    Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: September 15, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell, Dirk Finsinger
  • Publication number: 20090163556
    Abstract: The present invention relates to glycinamide derivatives of formula I, A-D-B??(I), wherein A, D, and B are as herein defined, as well as the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition, and a method of treatment comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: November 18, 2008
    Publication date: June 25, 2009
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
  • Publication number: 20090130098
    Abstract: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention.
    Type: Application
    Filed: January 18, 2007
    Publication date: May 21, 2009
    Applicant: Merck Patent GmbH
    Inventors: Simon Goodman, Martin Andreas Picard, Tom Mikkelsen, Johannes Nippgen, Ulrike Grimm, Roger Stupp, Michael Weller, Andreas Harstrick, Matthias Grell
  • Publication number: 20090035270
    Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: September 4, 2007
    Publication date: February 5, 2009
    Inventors: Matthias Grell, Simon Goodman, Curzio Ruegg
  • Patent number: 7476683
    Abstract: The present invention relates to glycinamide derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 13, 2009
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Oliver Schadt, Christiane Amendt, Frank Zenke, Christian Sirrenberg, Matthias Grell
  • Publication number: 20080312278
    Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumours.
    Type: Application
    Filed: November 14, 2006
    Publication date: December 18, 2008
    Inventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
  • Patent number: 7368295
    Abstract: The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: May 6, 2008
    Assignee: Fraunhofer-Gesellschaft zur Foderung der Angewandten Forschung E.V.
    Inventors: G√ľnter Tovar, Thomas Schiestel, Herwig Brunner, Klaus Pfizenmaier, Matthias Grell, Peter Scheurich, Angela Hammer
  • Publication number: 20070213374
    Abstract: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.
    Type: Application
    Filed: June 18, 2004
    Publication date: September 13, 2007
    Applicant: Merck Patent GmbH
    Inventors: David Bruge, Hans-Peter Buchstaller, Matthias Wiesner, Dirk Finsinger, Manfred Baumgarth, Christian Sirrenberg, Frank Zenke, Christian Amendt, Matthias Grell
  • Publication number: 20070191423
    Abstract: The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: February 1, 2005
    Publication date: August 16, 2007
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Lars Burgdorf, Dirk Finsinger, Christiana Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Publication number: 20070191353
    Abstract: Use of compounds of the formula (I), in which Ar1, Ar2 and Z have the meanings indicated in Patent Claim 1, for the prophylaxis and/or treatment of diseases in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular RAF kinases, plays a role.
    Type: Application
    Filed: January 31, 2005
    Publication date: August 16, 2007
    Inventors: Lars Burgdorf, Frank Stieber, Hans-Peter Buchstaller, Soheila Anzali, Christiane Amendt, Hartmut Greiner, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Publication number: 20070191444
    Abstract: The present invention relates to benzimidazolyl derivatives of formula (I), with the definition of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: February 14, 2005
    Publication date: August 16, 2007
    Inventors: Hans-Peter Buchstaller, Lars Burgdorf, Frank Stieber, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke